Diabetes drug risks reported ahead of FDA hearing
A new study released Monday by the Journal of the American Medical Association, “ties the controversial diabetes drug Avandia to a higher risk of heart problems, strokes and deaths in older adults.” (L. Tanner, AP Medical, 6/28). The leading author of the study is an FDA scientist, Dr. David Graham, who is hopeful that the results will cause the pill to be banned. The Food and Drug Administration hearing on Avandia’s safety is set to occur in two weeks. As a medical malpractice and products liability lawyer in Chicago, I am hopeful that the FDA will thoroughly review the results of the study and act accordingly.
The diabetes drug has been the subject of controversy for three years, “since a review of dozens of studies suggested it may raise the risk of heart attacks and heart-related deaths” In response, warnings were placed on the drug label, but the drug has remained on the market and is currently used by hundreds of thousands of Americans.
Bookmark: 
